Huluwa ST葫芦娃
9 significant filings since 29 May 2026: 3 on regulatory action, 2 on regulatory inquiry and 1 on share pledge, and 3 other kinds. The latest, on 15 Aug 2026: 海南葫芦娃药业集团股份有限公司关于收到海南证监局警示函的整改报告. On 15 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to fall by 4,166.73% to 4,996.67% from the same period a year earlier.
自 29 May 2026 起有 9 份重大公告：regulatory action 3 份、regulatory inquiry 2 份、share pledge 1 份，另有 3 类。最新一份（15 Aug 2026）：海南葫芦娃药业集团股份有限公司关于收到海南证监局警示函的整改报告。15 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期下降 4,166.73% 至 4,996.67%。
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥23亿 | ¥61亿 | 9th lowest of 66 · 66 家中第 9 低 | |
| Trailing P/E 市盈率 | — | 31.3x | No value 无数据 | |
| P/B 市净率 | 7.7x | 2.2x | 2nd highest of 65 · 65 家中第 2 高 | |
| Revenue Growth 营收增速 | -52.6% | -7.4% | 2nd lowest of 66 · 66 家中第 2 低 | |
| Profit Growth 净利增速 | -4,805.4% | -0.2% | Lowest of 66 · 66 家中第 1 低 | |
| Gross Margin 毛利率 | 16.4% | 56.9% | 2nd lowest of 66 · 66 家中第 2 低 | |
| Net Margin 净利率 | -46.5% | 9.6% | 2nd lowest of 66 · 66 家中第 2 低 | |
| Return on Equity 净资产收益率 | -31.9% | 3.0% | Lowest of 65 · 65 家中第 1 低 | |
| Debt to Assets 资产负债率 | 85.7% | 28.4% | 2nd highest of 66 · 66 家中第 2 高 | |
| Grade Score 评级得分 | 14 | 52 | 2nd lowest of 66 · 66 家中第 2 低 |
Statement figures are for the period to 30 Jun 2026, filed by 66 of 66 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，66 家同业中 66 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Yunnan Baiyao Group 云南白药 | ¥890亿 | 17.0x | 2.2x | 2.9% | 16.9% | 9.0% | C |
| Zhangzhou Pientzehuang Pharmaceutical 片仔癀 | ¥708亿 | 39.1x | 4.8x | -15.0% | 23.7% | 7.3% | C |
| China Resources Sanjiu Medical 华润三九 | ¥389亿 | 11.9x | 1.7x | 1.4% | 13.3% | 7.3% | C |
| Beijing Tong Ren Tang 同仁堂 | ¥320亿 | 33.0x | 2.3x | -14.2% | 11.2% | 5.2% | D |
| Guangzhou Baiyunshan Pharmaceutical Holdings 白云山 | ¥315亿 | 12.3x | 0.8x | 0.6% | 5.1% | 5.4% | D |
| Dong-E-E-Jiao 东阿阿胶 | ¥289亿 | 16.2x | 2.8x | 3.4% | 27.3% | 8.1% | C |
| Tianjin Pharmaceutical Da Ren Tang 达仁堂 | ¥271亿 | 31.9x | 4.6x | -7.4% | 26.2% | 9.1% | C |
| Shijiazhuang Yiling Pharmaceutical 以岭药业 | ¥253亿 | 18.4x | 2.3x | 0.9% | 18.6% | 6.7% | B |
| Jumpcan 济川药业 | ¥225亿 | 12.2x | 1.6x | -15.3% | 33.6% | 5.3% | C |
| Jilin Aodong Pharmaceutical Group 吉林敖东 | ¥209亿 | 6.6x | 0.7x | -8.5% | 198.7% | 6.5% | C |
| Tasly 天士力 | ¥204亿 | 16.7x | 1.6x | -2.0% | 21.1% | 7.0% | C |
| Guangdong Zhongsheng Pharmaceutical 众生药业 | ¥198亿 | 99.6x | 5.0x | -23.0% | 10.7% | 2.7% | C |
| Kangmei Pharmaceutical 康美药业 | ¥184亿 | 624.3x | 2.5x | -11.1% | 1.6% | 0.5% | D |
| Buchang Pharma 步长制药 | ¥153亿 | 65.0x | 1.5x | -11.7% | 9.2% | 4.9% | D |
| Huluwa ST葫芦娃 | ¥23亿 | — | 7.7x | -52.6% | -46.5% | -31.9% | E |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。